Xilio Therapeutics (XLO) EBITDA (2020 - 2026)

Xilio Therapeutics has disclosed EBITDA across 7 years of filings, most recently posting -$3.5 million for Q2 2026.

• In Q2 2026, EBITDA rose 75.7% year-over-year to -$3.5 million; the TTM figure through Jun 2026 stood at -$31.4 million (up 44.59% YoY), while the FY2025 annual figure was -$42.0 million, up 30.7% from the prior year.
• EBITDA came in at -$3.5 million for Q2 2026 at Xilio Therapeutics, up from -$14.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.9 million in Q3 2025 to a low of -$24.6 million in Q2 2022.
• Average EBITDA over 5 years is -$16.0 million, with a median of -$16.1 million recorded in 2023.
• Year-over-year, EBITDA slipped 28.47% in 2022 and soared 86.93% in 2025.
• Over 5 years, EBITDA stood at -$23.2 million in 2022, then grew by 21.74% to -$18.1 million in 2023, then rose by 24.83% to -$13.6 million in 2024, then rose by 13.16% to -$11.8 million in 2025, then jumped by 70.51% to -$3.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$3.5 million in Q2 2026, -$14.1 million in Q1 2026, and -$11.8 million in Q4 2025.